Back to top

Analyst Blog

Zacks Equity Research

Shire Progresses with ViroPharma Acquisition


 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Shire plc (SHPG - Analyst Report) recently announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) related to its previously announced acquisition of ViroPharma Incorporated has expired.

The expiration of the HSR waiting period brings a step closer to the acquisition of ViroPharma as it has satisfied one of the conditions of the tender offer.

However, the tender offer remains subject to certain conditions as set forth in the purchase offer.

As per the HSR, an investor who is seeking to acquire a 15% stake or a stake valued at more than $15 million in a security is required to file a form with the government. The form is called a premerger notification report (PNR) and the acquiring firm is required to pay a filing fee.

We remind investors that Shire recently announced that it will acquire ViroPharma for approximately $50 per share or $4.2 billion, in a bid to strengthen its portfolio of rare disease drugs. ViroPharma's lead drug Cinryze is approved in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adults with hereditary HAE. Cinryze complements Shire's Firazyr, indicated for the on-demand treatment of acute HAE attacks.

Shire expects the addition of Cinryze to its rare disease business unit to propel revenues to grow over $2 billion in 2014, accounting for approximately 40% of Shire's total product sales. Moreover, Shire expects to realize approximately $150 million of annual cost synergies across the business by 2015 from the acquisition. The acquisition is expected to be immediately accretive to Shire’s bottom line.

Shire’s efforts to realign its business structure to drive growth and innovation are noteworthy. The recently announced acquisition of ViroPharma will be a significant boost for the company’s rare disease portfolio and we expect accretion once the acquisition goes through.

Shire currently carries a Zacks Rank #2 (Buy). Right now, stocks like Jazz Pharmaceuticals (JAZZ - Analyst Report) and Forest Laboratories Inc. (FRX - Analyst Report) also look attractive. Both carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%